Literature DB >> 21476917

Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective.

Carolin Lackner1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an important complication of the metabolic syndrome. The increasing prevalence of the metabolic syndrome is paralleled by an increasing prevalence of NAFLD, which has become one of the most common chronic liver diseases. NAFLD comprises a morphological spectrum ranging from nonalcoholic fatty liver (NAFL), characterized by accumulation of fat in hepatocytes, to nonalcoholic steatohepatitis (NASH). The key histological features of NASH accepted by most pathologists include steatosis, hepatocellular ballooning and lobular inflammation, whereas, like in other chronic liver diseases, the presence of fibrosis is not considered a requirement for the diagnosis. The diagnosis of NASH and the distinction from NAFL carries important prognostic and therapeutic implications because NASH, in contrast to NAFL, is associated with an increased risk of progression to cirrhosis and hepatocellular carcinoma. Hepatocellular ballooning is a key feature required for the diagnosis of NASH and a component of currently used histological grading and staging systems of NAFLD. However, it represents an ill-defined form of liver cell injury associated with cell swelling and rounding of the cytoplasm, the detection of which is prone to intra- as well as inter-observer variation. Some of the factors that may contribute to ballooning are the rearrangement of the intermediate filament cytoskeleton, accumulation of small-droplet fat in the cytoplasm and dilation of the endoplasmic reticulum. The rearrangement of the intermediate filament cytoskeleton can be demonstrated by the loss of keratin 8/18 immunostaining of the cytoplasm, and may thus be evaluated in the future as a marker for the more objective detection of hepatocellular ballooning in NASH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21476917     DOI: 10.1586/egh.11.8

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  26 in total

Review 1.  Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame.

Authors:  Samar H Ibrahim; Petra Hirsova; Harmeet Malhi; Gregory J Gores
Journal:  Dig Dis Sci       Date:  2015-12-01       Impact factor: 3.199

2.  Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance.

Authors:  Tawfik Khoury; Ami Ben Ya'acov; Yehudit Shabat; Lidya Zolotarovya; Ram Snir; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

Review 3.  Transitions of histopathologic criteria for diagnosis of nonalcoholic fatty liver disease during the last three decades.

Authors:  Yoshihiro Ikura
Journal:  World J Hepatol       Date:  2014-12-27

4.  A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma.

Authors:  Christopher D Green; Cynthia Weigel; Ryan D R Brown; Pierre Bedossa; Mikhail Dozmorov; Arun J Sanyal; Sarah Spiegel
Journal:  FASEB J       Date:  2022-07       Impact factor: 5.834

5.  Hepatoprotection of Cinnamomum burmannii ethanolic extract against high-fat and cholesterol diet in Sprague-Dawley rats (Rattus norvegicus).

Authors:  Retno Susilowati; Abdul Malik Setiawan; Afida Fatimatuz Zahroh; Zadani Nabila Ashari; Alifatul Iffiyana; Ricky Hertanto; Muhammad Basyarudin; Isnaeni Hartiningsih; Mahrus Ismail
Journal:  Vet World       Date:  2022-04-15

Review 6.  Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.

Authors:  Robert F Schwabe; Ira Tabas; Utpal B Pajvani
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

Review 7.  The immunological and metabolic landscape in primary and metastatic liver cancer.

Authors:  Xin Li; Pierluigi Ramadori; Dominik Pfister; Marco Seehawer; Lars Zender; Mathias Heikenwalder
Journal:  Nat Rev Cancer       Date:  2021-07-29       Impact factor: 60.716

8.  A "Western Diet" promotes symptoms of hepatic steatosis in spontaneously hypertensive rats.

Authors:  Siân P Cartland; Nicole Tamer; Manisha S Patil; Belinda A Di Bartolo; Mary M Kavurma
Journal:  Int J Exp Pathol       Date:  2020-08-12       Impact factor: 1.925

9.  Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis.

Authors:  Yoshihiro Kamada; Maaya Akita; Yuri Takeda; Shin Yamada; Hideki Fujii; Yoshiyuki Sawai; Yoshinori Doi; Hitomi Asazawa; Kotarosumitomo Nakayama; Kayo Mizutani; Hironobu Fujii; Takayuki Yakushijin; Masanori Miyazaki; Hisao Ezaki; Naoki Hiramatsu; Yuichi Yoshida; Shinichi Kiso; Yasuharu Imai; Norifumi Kawada; Tetsuo Takehara; Eiji Miyoshi
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

10.  Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease.

Authors:  Ornella de Bari; Brent A Neuschwander-Tetri; Min Liu; Piero Portincasa; David Q-H Wang
Journal:  J Lipids       Date:  2011-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.